文献速递淋巴瘤白血病

EOMES与IL-10调控慢性淋巴细胞白血病中1型调节性CD4+ T细胞的抗肿瘤活性

EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2021-02-01

研究在慢性淋巴细胞白血病(CLL)患者淋巴结中检测到共表达细胞毒性分子、PD-1和EOMES的CD4+ T细胞。转录组和流式分析显示EOMES驱动1型调节性T细胞(TR1)特征性转录谱,该细胞群在Eμ-TCL1小鼠中积累;过继转移实验中EOMES缺陷CD4+ T细胞无法控制TCL1白血病,且该控制依赖IL-10受体信号。

要点

  • CLL患者淋巴结中积累共表达细胞毒性分子、PD-1和EOMES的CD4+ T细胞。
  • EOMES驱动CD4+ T细胞向表达IL-10和IFN-γ的TR1细胞分化。
  • TR1细胞控制TCL1白血病依赖IL-10受体信号,EOMES缺陷则丧失该能力。

核心结论

  • EOMES是表达IL-10的细胞毒性TR1细胞发育所必需,该细胞在CLL患者淋巴结中积累并以IL-10R依赖方式控制小鼠TCL1白血病。

研究设计与样本

  • 研究分析CLL或弥漫大B细胞淋巴瘤患者淋巴结中CD4+ T细胞,并结合Eμ-TCL1小鼠模型及过继转移至Rag2-/-小鼠的实验。

主要发现

  • 在CLL或DLBCL患者淋巴结中检测到共表达细胞毒性分子、PD-1和EOMES的CD4+ T细胞。
  • EOMES控制CD4+ T细胞中富含TR1细胞典型基因的独特转录特征,这些细胞表达IFN-γ、IL-10及包括PD-1在内的抑制性受体。
  • 具有细胞毒性能力的TR1细胞也在发生CLL样疾病的Eμ-TCL1小鼠中积累。
  • 在白细胞减少的Rag2-/-小鼠中,野生型CD4+ T细胞过继转移后控制TCL1白血病发展,而EOMES缺陷CD4+ T细胞未能控制。
  • Il10rb缺陷CD4+ T细胞抗白血病活性受损,表明TR1细胞介导的白血病控制需要IL-10R信号。

临床怎么用

  • 提示EOMES/IL-10轴及TR1细胞可能作为CLL免疫治疗的潜在靶点,但尚需临床研究验证。

局限性

  • 机制主要基于小鼠TCL1白血病模型和体外分析,人体内直接证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The transcription factor eomesodermin (EOMES) promotes interleukin (IL)-10 expression in CD4+ T cells, which has been linked to immunosuppressive and cytotoxic activities. We detected cytotoxic, programmed cell death protein-1 (PD-1) and EOMES co-expressing CD4+ T cells in lymph nodes (LNs) of patients with chronic lymphocytic leukemia (CLL) or diffuse large B-cell lymphoma. Transcriptome and flow cytometry analyses revealed that EOMES does not only drive IL-10 expression, but rather controls a unique transcriptional signature in CD4+ T cells, that is enriched in genes typical for T regulatory type 1 (TR1) cells. The TR1 cell identity of these CD4+ T cells was supported by their expression of interferon gamma and IL-10, as well as inhibitory receptors including PD-1. TR1 cells with cytotoxic capacity accumulate also in Eµ-TCL1 mice that develop CLL-like disease. Whereas wild-type CD4+ T cells control TCL1 leukemia development after adoptive transfer in leukopenic Rag2-/- mice, EOMES-deficient CD4+ T cells failed to do so. We further show that TR1 cell-mediated control of TCL1 leukemia requires IL-10 receptor (IL-10R) signaling, as Il10rb-deficient CD4+ T cells showed impaired antileukemia activity. Altogether, our data demonstrate that EOMES is indispensable for the development of IL-10-expressing, cytotoxic TR1 cells, which accumulate in LNs of CLL patients and control TCL1 leukemia in mice in an IL-10R-dependent manner.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Roessner PM, Llaó Cid L, Lupar E, et al. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia. 2021. PMID: 33526861. doi:10.1038/s41375-021-01136-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。